AbCellera Biologics (ABCL) Scheduled to Post Earnings on Tuesday

AbCellera Biologics (NASDAQ:ABCL) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

AbCellera Biologics (NASDAQ:ABCL) last posted its earnings results on Tuesday, February 20th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). The business had revenue of $9.18 million during the quarter, compared to the consensus estimate of $9.58 million. AbCellera Biologics had a negative return on equity of 12.36% and a negative net margin of 384.99%. On average, analysts expect AbCellera Biologics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

AbCellera Biologics Trading Up 4.7 %

Shares of NASDAQ ABCL opened at $4.03 on Friday. AbCellera Biologics has a 12-month low of $3.62 and a 12-month high of $8.05. The firm’s 50-day moving average price is $4.44 and its 200-day moving average price is $4.79. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of -7.75 and a beta of 0.42.

Wall Street Analysts Forecast Growth

ABCL has been the topic of a number of recent research reports. Stifel Nicolaus decreased their price objective on AbCellera Biologics from $21.00 to $17.00 and set a “buy” rating on the stock in a research report on Wednesday, February 21st. Benchmark upgraded AbCellera Biologics from a “hold” rating to a “buy” rating and set a $9.00 price target for the company in a research report on Thursday, February 22nd. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, AbCellera Biologics has an average rating of “Buy” and a consensus target price of $15.86.

AbCellera Biologics Company Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.